scholarly journals Retrospective evaluation of emergency department admissions in patients with ventricular assist device

2019 ◽  
pp. 102490791983353
Author(s):  
Ilhan Uz ◽  
Enver Özçete ◽  
Pelin Öztürk
Keyword(s):  
Heart Failure ◽  
Emergency Department ◽  
Ventricular Assist Device ◽  
International Normalized Ratio ◽  
Emergency Department Visits ◽  
Ventricular Assist Devices ◽  
Chronic Obstructive ◽  
Assist Device ◽  
Ventricular Assist ◽  
Obstructive Pulmonary Disease

Background: Ventricular assist devices, improve morbidity and survival in patients with end-stage heart failure. Objectives: To evaluate the major causes of emergency department admissions in patients with ventricular assist device support. Methods: The charts of 200,000 adult patients who presented to our emergency department between January 2016 and January 2018 were reviewed retrospectively. A total of 444 emergency department visits made by 99 patients with ventricular assist device were included in the study. Results: The annual incidence of emergency department admissions of patients with ventricular assist device was 0.1%. The mean age was 55.5 ± 11.1 years and 85.9% of the study population were men. The most commonly encountered diagnoses were abnormal international normalized ratio or international normalized ratio follow-up (18.2%); heart failure, non-specific chest pain, and chronic obstructive pulmonary disease (15.3%); minor/major bleeding (12.1%); neurological disorders such as ischemic stroke, transient ischemic attack, vertigo, migraine, and syncope (11.2%); non-device related infections (10.8%); ventricular tachycardia/fibrillation episode (8.5%); musculoskeletal disorders (7.2%); and device-related complications such as driveline infection and pump thrombosis (6.3%). Of the patients with bleeding, 31.1% had intracranial bleeding, 31.1% had epistaxis, 24% had gastrointestinal bleeding, 11.1% had hematuria, and 1.8% had gingival hemorrhage. Of the 15 patients who died, 73.3% were diagnosed with intracranial hemorrhage. Conclusion: Even though the mortality rates of patients with ventricular assist device tends to decrease, these patients still have significant morbidity due to the increase in the prevalence of ventricular assist device use. Except for device-related problems, emergency department management of this patient group does not differ much from other patient groups. As early diagnosis of any device-related problems is mandatory for decreasing mortality, emergency department physicians should be familiar with mechanical support systems.

scholarly journals Širdies nepakankamumo gydymas implantuojant dirbtinį skilvelį INCOR

2007 ◽  
Vol 5 (3) ◽  
pp. 0-0
Author(s):  
Kęstutis Ručinskas ◽  
Saulius Miniauskas ◽  
Gintaras Rasimavičius ◽  
Rimantas Bubulis ◽  
Stanislovas Stankevič ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
University Hospital ◽  
Ventricular Assist Devices ◽  
Assist Device ◽  
Ventricular Assist ◽  
Key Words Heart ◽  
Key Words Heart Failure ◽  
Vilnius University

Kęstutis Ručinskas1, Saulius Miniauskas1, Gintaras Rasimavičius1, Rimantas Bubulis2, Stanislovas Stankevič2, Vaclovas Jurkuvėnas2, Gitana Žemaitytė3, Vytė Valerija Maneikienė3, Vytautas Sirvydis1, Aleksandras Taucevičius41 Vilniaus universiteto Širdies chirurgijos centras, Santariškių g. 2, LT-08661 Vilnius2 Vilniaus universiteto ligoninės Santariškių klinikų Anesteziologijos,intensyviosios terapijos ir skausmo gydymo centras, Santariškių g. 2, LT-08661 Vilnius3 Vilniaus universiteto ligoninės Santariškių klinikų Širdies chirurgijos centras,Santariškių g. 2, LT-08661 Vilnius4 Vilniaus universiteto Širdies ir kraujagyslių ligų klinika, Santariškių g. 2, LT-08661 VilniusEl paštas: [email protected] Dirbtinis implantuojamas pastovios tėkmės kairysis skilvelis INCOR Vilniaus universiteto Širdies chirurgijos centre naudojamas nuo 2003 metų. Pacientams, kuriems nustatytas kraštutinis širdies nepakankamumas, implantuota 14 dirbtinių skilvelių. Po prijungimo 9 pacientai buvo išrašyti į namus, 4 iš jų sulaukė širdies persodinimo operacijos. Šiuo metu ambulatoriškai stebimi 4 pacientai, kuriems implantuotas INCOR skilvelis. Bendras pacientų stebėjimo laikas yra daugiau kaip 8,5 metų. Dirbtinio skilvelio INCOR implantacija yra labai efektyvus atrinktos grupės pacientų širdies nepakankamumo gydymo būdas. Pagrindiniai žodžiai: širdies nepakankamumas, dirbtinis skilvelis, širdies persodinimas Treatment of heart failure by implanting an INCOR left ventricular assist device Kęstutis Ručinskas1, Saulius Miniauskas1, Gintaras Rasimavičius1, Rimantas Bubulis2, Stanislovas Stankevič2, Vaclovas Jurkuvėnas2, Gitana Žemaitytė3, Vytė Valerija Maneikienė3, Vytautas Sirvydis1, Aleksandras Taucevičius41 Cardial Surgery Centre, Vilnius University, Santariškių str. 2, LT-08661 Vilnius, Lithuania2 Vilnius University Hospital „Santariškių klinikos“, Anesthesiology,Intensive Care and Pain Management Center, Santariškių str. 2, LT-08661 Vilnius, Lithuania 3 Cardial Surgery Centre of Vilnius University Hospital „Santariškių klinikos“,Santariškių str. 2, LT-08661 Vilnius, Lithuania4 Vilnius University, Clinic of Cardiovascular Diseases,Santariškių str. 2, LT-08661 Vilnius, LithuaniaE-mail: [email protected] Continuous blood flow ventricular assist devices, INCOR, are used at Vilnius University Cardial Surgery Centre since 2003. Fourteen of them were implanted to terminal heart failure patients. After the procedure, 9 patients were discharged home and 4 received heart transplant. At the present time, four patients with INCOR are being observed at home. The cumulative time of the patients with the INCOR assist device is 8.5 years. Effective treatment for a selected group of patients with heart failure is ventricular assist device INCOR implantation. Key words: heart failure, assist device, heart transplantation

scholarly journals Implication of Hemodynamic Assessment during Durable Left Ventricular Assist Device Support

Medicina ◽  
2020 ◽  
Vol 56 (8) ◽  
pp. 413
Author(s):  
Teruhiko Imamura ◽  
Nikhil Narang
Keyword(s):  
Heart Failure ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Left Ventricular Assist Devices ◽  
Assist Device ◽  
Ventricular Assist ◽  
Hemodynamic Assessment ◽  
Left Ventricular Assist

Durable left ventricular assist device therapy has improved survival in patients with advanced heart failure refractory to conventional medical therapy, although the readmission rates due to device-related comorbidities remain high. Left ventricular assist devices are designed to support a failing left ventricle through relief of congestion and improvement of cardiac output. However, many patients still have abnormal hemodynamics even though they may appear to be clinically stable. Furthermore, such abnormal hemodynamics are associated with an increased risk of future adverse events including recurrent heart failure, gastrointestinal bleeding, stroke, and pump thrombosis. Correction of residual hemodynamic derangements post-implantation may be a target in improving longitudinal clinical outcomes during left ventricular assist device support. Automatic and timely device speed adjustments considering a patients’ hemodynamic status (i.e., with a smart pump) are potential improvements in forthcoming devices.

scholarly journals Biomarkers in Advanced Heart Failure

2020 ◽  
Vol 13 (7) ◽  
Author(s):  
Rahul S. Loungani ◽  
Robert J. Mentz ◽  
Richa Agarwal ◽  
Adam D. DeVore ◽  
Chetan B. Patel ◽  
...  
Keyword(s):  
Heart Failure ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Advanced Heart Failure ◽  
Ventricular Assist Devices ◽  
Left Ventricular Assist Devices ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist

Biomarkers have a well-defined role in the diagnosis and management of chronic heart failure, but their role in patients with left ventricular assist devices and cardiac transplant is uncertain. In this review, we summarize the available literature in this patient population, with a focus on clinical application. Some ubiquitous biomarkers, for example, natriuretic peptides and cardiac troponin, may assist in the diagnosis of left ventricular assist device complications and transplant rejection. Novel biomarkers focused on specific pathological processes, such as left ventricular assist device thrombosis and profiling of leukocyte activation, continue to be developed and show promise in altering the management of the advanced heart failure patient. Few biomarkers at this time have been assessed with sufficient scrutiny to warrant broad, universal application, but encouraging limited data and large potential for impact should prompt ongoing investigation.

scholarly journals Novel Risk Model to Predict Emergency Department Associated Mortality for Patients Supported With a Ventricular Assist Device: The Emergency Department–Ventricular Assist Device Risk Score

2022 ◽  
Author(s):  
Jonathan B. Edelson ◽  
Jonathan J. Edwards ◽  
Hannah Katcoff ◽  
Antara Mondal ◽  
Feiyan Chen ◽  
...  
Keyword(s):  
Emergency Department ◽  
Risk Score ◽  
Ventricular Assist Device ◽  
Risk Model ◽  
Ventricular Assist Devices ◽  
Assist Device ◽  
Ventricular Assist ◽  
Assist Devices ◽  
Predictors Of Mortality ◽  
Risk Of Death

Background The past decade has seen tremendous growth in patients with ambulatory ventricular assist devices. We sought to identify patients that present to the emergency department (ED) at the highest risk of death. Methods and Results This retrospective analysis of ED encounters from the Nationwide Emergency Department Sample includes 2010 to 2017. Using a random sampling of patient encounters, 80% were assigned to development and 20% to validation cohorts. A risk model was derived from independent predictors of mortality. Each patient encounter was assigned to 1 of 3 groups based on risk score. A total of 44 042 ED ventricular assist device patient encounters were included. The majority of patients were male (73.6%), <65 years old (60.1%), and 29% presented with bleeding, stroke, or device complication. Independent predictors of mortality during the ED visit or subsequent admission included age ≥65 years (odds ratio [OR], 1.8; 95% CI, 1.3–4.6), primary diagnoses (stroke [OR, 19.4; 95% CI, 13.1–28.8], device complication [OR, 10.1; 95% CI, 6.5–16.7], cardiac [OR, 4.0; 95% CI, 2.7–6.1], infection [OR, 5.8; 95% CI, 3.5–8.9]), and blood transfusion (OR, 2.6; 95% CI, 1.8–4.0), whereas history of hypertension was protective (OR, 0.69; 95% CI, 0.5–0.9). The risk score predicted mortality areas under the curve of 0.78 and 0.71 for development and validation. Encounters in the highest risk score strata had a 16‐fold higher mortality compared with the lowest risk group (15.8% versus 1.0%). Conclusions We present a novel risk score and its validation for predicting mortality of patients with ED ventricular assist devices, a high‐risk, and growing, population.

Arrhythmias in children with ventricular assist devices

2013 ◽  
Vol 25 (2) ◽  
pp. 255-260
Author(s):  
W. Buck Kyle ◽  
Jamie Decker ◽  
Scott L. Macicek ◽  
Santiago O. Valdes ◽  
David Morales ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ventricular Assist Device ◽  
Transplant Rejection ◽  
Decompensated Heart Failure ◽  
Ventricular Assist Devices ◽  
Assist Device ◽  
Ventricular Assist ◽  
Assist Devices ◽  
Risk Of Death ◽  
The Impact

AbstractBackground: Children with decompensated heart failure are at high risk for arrhythmias, and ventricular assist device placement is becoming a more common treatment strategy. The impact of ventricular assist devices on arrhythmias and how arrhythmias affect the clinical course of this population are not well described. Methods and results: A single-centre retrospective analysis of children receiving a ventricular assist device between 1998 and 2011 was performed. In all, 45 patients received 56 ventricular assist devices. The median age at initial placement was 13 years (interquartile range 6–15). The median duration of support was 10 days (range 2–260). The aetiology of heart failure included cardiomyopathy, transplant rejection, myocarditis, and congenital heart disease. In all, 32 patients (71%) had an arrhythmia; 19 patients (42%) had an arrhythmia before ventricular assist device and eight patients (18%) developed new arrhythmias on ventricular assist device. Ventricular tachycardia was most common (25/32, 78%). There was no correlation between arrhythmia and risk of death or transplantation (p=0.14). Of the 15 patients who weaned from ventricular assist device, post-ventricular assist device arrhythmias occurred in nine (60%), with five (33%) having their first arrhythmia after weaning. Patients with ventricular dysfunction after ventricular assist device were more likely to have arrhythmias (p<0.02). Conclusions: Arrhythmias, especially ventricular, are common in children requiring ventricular assist device. They frequently persist for those able to wean from ventricular assist device.

Use of an Intrapericardial Continuous Flow Ventricular Assist Device in a 4-Year-Old Child Weighing 12 Kilograms

2016 ◽  
Vol 19 (2) ◽  
pp. 087 ◽  
Author(s):  
Korhan Erkanlı ◽  
Mehmet Kaya ◽  
Murat Avşar ◽  
İhsan Bakır
Keyword(s):  
Heart Failure ◽  
Ventricular Assist Device ◽  
Continuous Flow ◽  
Circulatory System ◽  
Ventricular Assist Devices ◽  
Bridge To Transplantation ◽  
Assist Device ◽  
Ventricular Assist ◽  
Low Weight ◽  
End Stage

Ventricular assist devices are implanted in patients with intractable heart failure as a bridge to cardiac transplantation to support the circulatory system mechanically. We present a report of a continuous flow ventricular assist device successfully placed as a bridge to transplantation in the intrapericardium of a petite-sized child with a BSA of 0.56 m2. Not only is the use of an intrapericardial, continuous-flow, centrifugal pump feasible for destination therapy, but also for low-weight pediatric patients with end-stage heart failure as a bridge to transplantation when there is chronic shortage of donor organs for heart transplantation. Consequently, the HeartWare system has been implanted in smaller patients with acceptable results, and this patient may be the youngest ever reported.

Ventricular Assist Devices

2012 ◽  
Vol 23 (1) ◽  
pp. 69-83 ◽  
Author(s):  
Genevieve O’Shea
Keyword(s):  
Heart Failure ◽  
Ventricular Assist Device ◽  
Advanced Heart Failure ◽  
Ventricular Assist Devices ◽  
Circulatory Support ◽  
Nursing Management ◽  
Assist Device ◽  
Physiological Basis ◽  
Ventricular Assist ◽  
Assist Devices

Patients with advanced heart failure have limited treatment options despite advances in medical management. Ventricular assist devices represent a surgical option that offers improved end-organ function, survival, and quality of life. Postoperative nursing management involves the most complicated aspects of care following cardiac surgery as well as issues unique to advanced heart failure and mechanical circulatory support. Despite growing numbers of ventricular assist device implants, literature about the challenging care of patients following ventricular assist device implantation is limited. This article focuses on the physiological basis for postoperative nursing management strategies and the most important complications of which critical care nurses need to be aware.

Sign in / Sign up

Export Citation Format

Share Document